Additionally, a retrospective analysis within the AMTEC trial (NCT03801369) found a significant correlation between gut microbiome diversity and tumor biomarkers, including PD-L1 expression, tumor immune cell density, TILs, mutation signatures, and interferon gene signatures, among 10 patients with TNBC receiving olaparib and durvalumab. This evidence concerns the gene CD274 and neoplasm.